From friend to foe: when your immune system turns against you and how to turn it back

The immune system can go haywire in autoimmune diseases and cancer. While this may affect the body in different ways, the key to treating these diseases is interconnected. 

AbbVie Presents Initial Data from Pivotal Phase-3 Trial Evaluating the Efficacy and Safety of HUMIRA® (adalimumab) for Moderate to Severe Fingernail Psoriasis in Adult Patients at Psoriasis 2016 Congress

PARIS, July 7, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today will present findings of a Phase 3 study of patients with moderate to severe psoriasis demonstrating that nearly half of adult patients treated with HUMIRA® (adalimumab) achieved at least a 75 percent improvement in their moderate to severe fingernail psoriasis compared to patients receiving placebo. The study will be presented at Psoriasis 2016 - 5th Congress of the Psoriasis International Network taking place July 7 - 9 in Paris, alongside additional abstracts.

AbbVie's HUMIRA® (adalimumab) Receives U.S. Food and Drug Administration Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis

NORTH CHICAGO, Ill., June 30, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® (adalimumab) for the treatment of non-infectious intermediate, posterior and panuveitis. HUMIRA is now the first and only FDA-approved non-corticosteroid therapy available for adults with non?infectious intermediate, posterior and panuveitis. This approval marks the 10th approved indication for HUMIRA in the United States for immune-mediated diseases.

AbbVie Scholarship Programs Recognize Exceptional Students Living with Chronic Inflammatory Diseases

NORTH CHICAGO, Ill., June 16, 2016 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, today announced the recipients of the AbbVie Crohn's & Colitis Scholarship and the AbbVie Rheumatology Scholarship. These scholarships provide financial support for exceptional students living with inflammatory bowel disease, including Crohn's disease or ulcerative colitis; rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis, as they pursue higher education goals.

AbbVie's Research and Commitment to Helping People Living with Rheumatologic Diseases Highlighted at the Annual European Congress of Rheumatology (EULAR 2016)

NORTH CHICAGO, Ill., June 2, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that data on HUMIRA® (adalimumab), investigational medicines and research, including real-world evidence, aiming to improve clinical outcomes for patients with rheumatologic diseases, will be presented at the Annual European Congress of Rheumatology (EULAR 2016), June 8 – 11, in London. These data add to the body of evidence supporting the safety and efficacy of adalimumab, an anti-TNF therapy, and AbbVie's continued commitment to innovation across immunology.

AbbVie's HUMIRA® (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision[1]

NORTH CHICAGO, Ill., May 27, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for HUMIRA® (adalimumab) for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids or in whom corticosteroid treatment is inappropriate. HUMIRA can also decrease corticosteroid use in corticosteroid-dependent patients.

AbbVie to Present at the Jefferies 2016 Healthcare Conference

NORTH CHICAGO, Ill., May 26, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 7:30 a.m. Central time.

IL-23 Inhibitor Risankizumab Induces Remission in Phase II Study in Patients with Moderate-to-Severe Crohn's Disease

INGELHEIM, Germany, and NORTH CHICAGO, Ill., May 24, 2016 /PRNewswire/ -- Results were presented today from a proof-of-concept, Phase II, randomized, placebo-controlled study (NCT02031276) in Crohn's disease with investigational biologic, risankizumab (formerly BI 655066), a compound from Boehringer Ingelheim research and recently licensed by AbbVie (NYSE: ABBV). Risankizumab was shown to be more effective than placebo in patients with moderately-to-severely active Crohn's disease.1 These interim results are the first to be reported in this indication with risankizumab, which selectively blocks IL-23 through the specific targeting of the IL-23p19 subunit.1  After 12 weeks, 24% and 37% of patients achieved clinical remission (no symptoms or very mild symptoms of disease) with 200 mg and 600 mg risankizumab, respectively, compared with 15% of patients receiving placebo*1. Endoscopic remission (normalization of the lining of bowel as seen during an endoscopy) was achieved by 15% and 20% of patients receiving 200 mg and 600 mg risankizumab, respectively, compared with three percent of patients receiving placebo.1

World Health Organization (WHO) Publishes Global Report on Psoriasis

The report aims to raise awareness of psoriasis and fight negative perceptions of people living with disease. The complexity of the disease requires a more holistic “whole person” approach to care.

AbbVie's Leadership in Gastroenterology Showcased at Digestive Disease Week® with New HUMIRA® (adalimumab) Long-Term, Real-World Research and Promising Anti-IL-23 Antibody Late-Breaking Data

NORTH CHICAGO, Ill., May 19, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, will present 13 abstracts across inflammatory bowel diseases including adult and pediatric Crohn's disease, and ulcerative colitis at the Digestive Disease Week (DDW) Annual Meeting, May 21-24, 2016, in San Diego.  AbbVie and Boehringer Ingelheim will also present late-breaking data on risankizumab, formerly known as BI 655066, an investigational anti-IL-23 monoclonal biologic antibody.